叶酸对妊娠期高血压疾病患者血清Hcy、尿蛋白及母婴结局的影响(1)
【摘要】 目的：探究葉酸对妊娠期高血压疾病(HDCP)患者母婴结局、体内尿蛋白、血清中Hcy表达水平的影响。方法：将在本院进行治疗的HDCP患者随机分为叶酸组(FO组)，常规治疗组(CT组)，各60例;同时选取本院正常体检的正常妊娠孕妇120例为健康组(HE组)。CT组、FO组和HE组患者一般资料差异无统计学意义(P>0.05)。通过分析CT组、FO组和HE组三组患者尿蛋白、血清中Hcy表达水平、平均动脉压、血清中Cys-C表达水平、母婴结局的差异性来探究叶酸对妊娠期高血压疾病患者母婴结局、体内尿蛋白、血清中Hcy表达水平的影响。结果：治疗后，与HE组比较，CT组、FO组患者体内尿蛋白、平均动脉压表达均较高，与CT组比较，FO组患者体内尿蛋白等指标表达量均较低(P<0.05)。治疗后，与HE组比较，CT组、FO组患者体内Hcy、Cys-C表达水平均较高，与CT组比较，FO组患者体内Hcy、Cys-C表达水平较低(P<0.05)。与HE组相比较，CT组、FO组患者母婴结局不良率较高，与CT组相比较，FO组患者母婴结局不良率较低，三组不良妊娠结局发生率比较差异有统计学意义(P<0.05)。结论：叶酸对妊娠期高血压疾病患者具有一定的治疗效果，能够显著改善患者体内Hcy、尿蛋白等相关指标，降低母婴结局的不良情况发生率。
【关键词】 母婴结局 尿蛋白 妊娠期高血压疾病 叶酸 Hcy
doi：10.14033/j.cnki.cfmr.2020.24.001 文献标识码 A 文章编号 1674-6805(2020)24-000-03
[Abstract] Objective： To explore the effects of Folic Acid on maternal and infant outcomes， urine protein in the body， and serum Hcy expression levels in patients with hypertensive disorder complicating pregnancy (HDCP). Method： The HDCP patients treated in this hospital were randomly divided into Folic Acid group (FO group)， conventional treatment group (CT group)， 60 cases in each; 120 normal pregnant women with normal physical examination in this hospital were selected as the healthy group (HE group). There was no statistically significant difference in general information of patients in CT group， FO group and HE group (P>0.05). By analyzing the differences in urine protein， serum Hcy expression level， mean arterial pressure， serum Cys-C expression level， and maternal and infant outcomes among the three groups of patients to explore the effects of Folic Acid on patients with pregnancy-induced hypertension. Result： After treatment， compared with the HE group， the expression of urine protein and mean arterial pressure in the CT group and the FO group were higher. Compared with the CT group， the expression of urine protein and other indicators in the FO group were lower (P<0.05). After treatment， compared with the HE group， the expression levels of Hcy and Cys-C in the CT group and the FO group were higher. Compared with the CT group， the expression levels of Hcy and Cys-C in the FO group were lower (P<0.05). Compared with the HE group， the patients in the CT group and the FO group had higher rates of adverse maternal and infant outcomes. Compared with the CT group， the patients in the FO group had lower rates of adverse pregnancy outcomes. There was a statistically significant difference in the incidence of adverse pregnancy outcomes among the three groups (P<0.05). Conclusion： Folic Acid has a certain therapeutic effect on patients with HDCP. It can significantly improve Hcy， urine protein and other related indicators in the patients， and reduce the incidence of adverse maternal and infant outcomes., 百拇医药(王玲 梁雄 吴妍芝)
【关键词】 母婴结局 尿蛋白 妊娠期高血压疾病 叶酸 Hcy
doi：10.14033/j.cnki.cfmr.2020.24.001 文献标识码 A 文章编号 1674-6805(2020)24-000-03
[Abstract] Objective： To explore the effects of Folic Acid on maternal and infant outcomes， urine protein in the body， and serum Hcy expression levels in patients with hypertensive disorder complicating pregnancy (HDCP). Method： The HDCP patients treated in this hospital were randomly divided into Folic Acid group (FO group)， conventional treatment group (CT group)， 60 cases in each; 120 normal pregnant women with normal physical examination in this hospital were selected as the healthy group (HE group). There was no statistically significant difference in general information of patients in CT group， FO group and HE group (P>0.05). By analyzing the differences in urine protein， serum Hcy expression level， mean arterial pressure， serum Cys-C expression level， and maternal and infant outcomes among the three groups of patients to explore the effects of Folic Acid on patients with pregnancy-induced hypertension. Result： After treatment， compared with the HE group， the expression of urine protein and mean arterial pressure in the CT group and the FO group were higher. Compared with the CT group， the expression of urine protein and other indicators in the FO group were lower (P<0.05). After treatment， compared with the HE group， the expression levels of Hcy and Cys-C in the CT group and the FO group were higher. Compared with the CT group， the expression levels of Hcy and Cys-C in the FO group were lower (P<0.05). Compared with the HE group， the patients in the CT group and the FO group had higher rates of adverse maternal and infant outcomes. Compared with the CT group， the patients in the FO group had lower rates of adverse pregnancy outcomes. There was a statistically significant difference in the incidence of adverse pregnancy outcomes among the three groups (P<0.05). Conclusion： Folic Acid has a certain therapeutic effect on patients with HDCP. It can significantly improve Hcy， urine protein and other related indicators in the patients， and reduce the incidence of adverse maternal and infant outcomes., 百拇医药(王玲 梁雄 吴妍芝)